M&As this week: Biosynex S.A., Biovica International AB, Pentax Corporation

18 May 2016 (Last Updated May 18th, 2016 18:30)

Biosynex S.A., a manufacturer of in-vitro diagnostic kits, has entered an agreement to acquire Fumouze Diagnostics SAS.

Pentax video processor

Biosynex S.A., a manufacturer of in-vitro diagnostic kits, has entered an agreement to acquire Fumouze Diagnostics SAS. The acquisition will enable Biosynex to boost its sales force in the rapid diagnostic tests sector in France.

Biosynex, based in France, plans to become the European leader in the rapid diagnostics market by 2020.

cSens AB has been acquired by Biovica International AB, a bio-diagnostic company, in a move by the latter to enhance its diagnostic expertise using cSens' diagnostic platform.

The acquirer company also intends to develop more pre-clinical measurements in cancer cell cultures and animal models through the transaction.

cSens AB is the developer of a PCR-based platform that corresponds to tumour proliferation and cancer aggressiveness and helps in the analysis of serum thymidine kinase (TK) enzyme activity.

The acquisition also provides Biovica with an opportunity to develop new drugs and treatments for cancer.

Pentax Corporation owns more than 90% stake in Sistemas Integrales de Medicina following the acquisition of an additional 15% stake in the medical equipment distributor.

Pentax is a subsidiary of Hoya Corporation and is engaged in the medical device sector. It plans to boost its business in Spain and Portugal through the acquisition and become a leading medical device company in Europe.

The company purchased a 75% stake in Sistemas Integrales de Medicina last year at an estimated consideration of €2.25m ($3m).

Zhejiang Dian Diagnostics has entered an agreement with Deqing Fu Ying and Deqing Schwab Investment to acquire 65% stake in Inner Mongolia Medical Technology, a medical diagnostic products and services provider.

"The acquisition is estimated to be worth CNY253.5m ($38.8m) and leaves Hohhot Jinfeng Xin Medical Devices with a 35% stake in the target company."

The acquisition is estimated to be worth CNY253.5m ($38.8m) and leaves Hohhot Jinfeng Xin Medical Devices with a 35% stake in the target company.

Nanosphere, a molecular diagnostics platform provider, will be acquired by Luminex Corporation for $1.35 per share in an all-cash transaction valued at $58m.

Under the terms of the agreement, Luminex will assume Nanosphere's $25m in debts. The acquisition is expected to be closed on or before 1 July 2016 and is subject to customary closing conditions.

Luminex intends to strengthen its product offerings and future product pipeline through the acquisition.


Image: A Pentax medical device. Photo: Business Wire.